In Vivo Ready™ Anti-Mouse CD274 (PD-L1, B7-H1) (10F.9G2) Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| FC, FA |
---|---|
Isotype | Rat IgG2b, kappa |
Concentration | 2 mg/mL |
Reactivity | Mouse |
Formulation | 10 mM NaH2PO4, 150 mM NaCl, pH7.2 |
Host | Rat |
Gene ID | 60533 |
---|---|
Gene Name | Cd274 |
Alternative Name(s) | B7H1, PDL-1, PDL1 |
Format | In Vivo Ready™ |
Preparation | This monoclonal antibody preparation was purified from tissue culture supernatant via affinity chromatography. For In Vivo Ready™ (IVR) products, each preparation is also evaluated for endotoxin levels using the LAL assay. It is recommended to store the product undiluted at 4°C. Do not freeze. |
Application Notes | This purified format is guaranteed to be >90% pure as determined by SDS-PAGE analysis. Citations are provided as a convenience to you - please consult Materials and Methods sections for additional details about the use of any product in these publications. |
Endotoxin Level | Less than or equal to 0.01 EU/ug, as determined by the LaL assay |
Storage Conditions | 2-8°C |
Chen A, Ahlen G, Brenndorfer ED, Brass A, Holmstrom F, Chen M, Soderholm J, Milich DR, Frelin L, and Sallberg M. 2011. J. Immunol. 186:5107-5118. (in vivo depletion)
Zhang L, Gajewski TF, and Kline J. 2009. Blood. 114:1545-1552. (in vivo blocking)
Rivas MN, Weatherly K, Hazzan M, Vokaer B, Dremier S, Gaudray F, Goldman M, Salmon I, and Braun MY. 2009. 183:4284-4291. (in vitro blocking)
Brooks DG, Ha S-J, Elsaesser H, Sharpe AH, Freeman GJ, and Oldstone MBA. 2008. Proc. Natl. Acad. Sci. 105:20428-20433. (in vivo blocking)
Koehn BH, Ford ML, Ferrer IR, Borom K, Gangappa S, Kirk AD, and Larsen CP. 2008. J. Immunol. 181:5313-5322. (in vivo blocking)
Provided below are standard protocols that you may find useful for product applications.
Background
The 10F.9G2 antibody is specific for mouse CD274, more commonly known as PD-L1 or B7-H1, which acts as a ligand for the T cell co-regulatory receptor PD-1 (CD279). This interaction modulates T cell antigen receptor (TCR) signaling and therefore T cell activation. PD-L1 binding to PD-1 expressed on CD4- CD8- thymocytes participates in the processes of clonal selection, elimination of autoreactive lymphocytes, and development of tolerance. PD-L1 may also bind PD-1 following the receptor’s inducible expression on activated, mature T cells, where it has been proposed to limit T cell activation. PD-L1 is one of a group of “B7” ligands whose interactions with the CD28 receptor family, also including CTLA-4 (CD152), provide a balance of co-stimulatory /co-inhibitory signaling important in T cell activation, tolerance, and autoimmunity.
The 10F.9G2 antibody may be used as a marker for PD-L1 expression on T and B cells, NK cells and on dendritic cells. It is also widely used for analysis of receptor-ligand interaction and function(s) in vitro and in vivo.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.